<DOC>
	<DOC>NCT02074514</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + ribavirin (RBV) in treatment-naive adults with chronic genotype 1 or 3 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCV RNA â‰¥10^4 IU/mL at screening Confirmed chronic HCV genotype 1 or 3 infection HCV treatment naive Approximately 30% of individuals may have compensated cirrhosis at screening Any other chronic liver disease Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Current or prior history of clinical hepatic decompensation Contraindication to RBV therapy, e.g., history of clinically significant hemoglobinopathy (sickle cell disease, thalassemia). Chronic use of systemically administered immunosuppressive agents History of solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>